Search
PSM submits written testimony on Michigan Senate Bills 3, 4, and 5 On April 23, The Partnership for Safe Medicines submitted written testimony in opposition to Michigan Senate Bills 3, 4, and 5, which would create a prescription drug affordability board (PDAB) in Michigan to establish upper payment limits on certain medicines. Read the testimony to learn why Michigan’s proposed…
Read More
Prescription Drug Affordability Board Activity through April 16, 2025 Activities Summary Colorado: Colorado’s PDAB met on April 11, 2025, where it addressed an error in All-Payer Claims Database data and how it affected affordability review information for Enbrel, Cosentyx and Stelara. Maryland: Maryland’s PDAB did not meet in April. Oregon: Oregon’s PDAB met on April 16, 2025 to review a…
Read More
A Kentucky doctor treated weight loss patients with research chemicals; CBP seized 90,000 alprazolam pills being smuggled into the U.S.
Read More
The FDA and Novo Nordisk are warning the public about counterfeit Ozempic injections circulating in the U.S. drug supply chain. The falsified products, labeled with lot number PAR0362 and serial numbers beginning with 51746517, were seized by the FDA on April 9, 2025. Their contents and safety are unverified and pose serious health risks.
Read More
Prescription Drug Affordability Board Activity through March 31, 2025 Activities Summary Colorado: Colorado’s PDAB cancelled its March meetings. Maryland: Maryland’s PDAB met on March 24, 2025 to begin a cost review of Farxiga and review feedback about updates to PDAB regulations. Oregon: Board members met on March 19, 2025, where they elected a subset of drugs for affordability reviews. 31…
Read More
PSM is seeking input on developing a set of best practices to reduce sales of counterfeit and diverted medicines on online pharmacy-to-pharmacy marketplaces.
Read More
The FDA announced that it had seized counterfeit Ozempic injections on April 9. PSM testified at a congressional hearing.
Read More
A study examined the 130 enforcement actions undertaken by the U.S. Food and Drug Administration’s Office of Criminal Investigations from 2016 through 2021.
Read More